Starling Oncology (STLN) Insider Trades, Congress & Funds

Smart money at a glance

Filings to Nov 14, 2026

Net selling: insiders sold $13.3M and bought $176K on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersForm 4, 90 days: -$13.1M net
CongressSTOCK Act, 180 days: None
Big funds13F, latest quarter: No large changes
Federal contractsUSAspending.gov, 12 months: No awards

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

Unlock the full results

Questions about STLN filings

Are insiders buying or selling Starling Oncology, Inc. (STLN) stock?

Net selling: insiders sold $13.3M and bought $176K of STLN stock on the open market in the 90 days to Nov 14, 2026, according to SEC Form 4 filings. $1.9M of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Chernett, Jorey (10% owner), who sold $11.4M. The latest filing was on Nov 10, 2026.

Which members of Congress have traded STLN recently?

None. No member of Congress disclosed a STLN trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this STLN smart-money data?

This summary uses filings available on Nov 14, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

Smart money on STLN

Lean short1 source:
- Insiders

Top traders
No tracked positions at the last update
Insiders
- Brad Hively, sold $1.9M, scheduled plan sale, filed Aug 24
- Jorey Chernett, sold $11.4M, open market, filed Nov 10
Lean short · thin2 sales · $13.3M
1 of 2 on scheduled plans. Form 4 filings.
Congress
No recent politician filings found
Funds
No recent fund filings found
Influencers
No recent posts found

Each bar is 100% of that source’s money. The notch marks an even split.

Lean is the direction of the latest moves. Descriptive, not advice.

Questions about STLN filings

Are insiders buying or selling Starling Oncology, Inc. (STLN) stock?

Which members of Congress have traded STLN recently?

None. No member of Congress disclosed a STLN trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this STLN smart-money data?

Insiders

What insiders are doing

2 trades · 6 mo

Sold$13.3M

Sells (2)

CJ
Chernett Jorey
10% · Nov 10
$11.4M
sold
Signals like this: n=8123, 50% finished lower at D15, median -0.1% vs SPY +0.6%
HB
Hively Brad
Dir · Aug 24
$1.9M
sold

Unlock everything for $29/month

Unlock for $29/month

Reported Nov 5, 2026

Earnings came in $0.06 a share below what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Nov 5, 2026

Period ending

Sep 30, 2026

Earnings per share

-$0.13-$0.06 miss

-$0.07 expected

Revenue

$169.8M

SEC filing

Next report

What the street expects next

Estimates as of Nov 13, 2026

EPS expected

-$0.01

-$0.04 to $0.03

Revenue expected

$177.9M

4 analysts

Last 30 days

2up0down

Analysts raising estimates

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Sep 30, 2026Reported Nov 5, 2026	-$0.13est. -$0.07	-$0.06miss	$169.8MSEC filing	+24.3%from $136.6M
Jun 30, 2026Reported Aug 6, 2026	-$0.08est. -$0.07	-$0.01miss	$161.3MSEC filing	+34.6%from $119.8M
Mar 31, 2026Reported May 8, 2026	-$0.02est. -$0.09	+$0.07beat	$147.4MSEC filing	+41.2%from $104.4M
Dec 31, 2025Reported Mar 13, 2026	-$0.06est. -$0.09	+$0.03beat	$142.0MYahoo Finance	No year-ago quarter
Sep 30, 2025Reported Nov 14, 2025	-$0.14est. -$0.11	-23.57%miss	$136.6MSEC filing	+36.7%from $99.9M
Jun 30, 2025Reported Aug 14, 2025	-$0.15est. -$0.12	-25.00%miss	$119.8MSEC filing	+21.5%from $98.6M
Mar 31, 2025Reported May 15, 2025	-$0.21Reported	No estimate	$104.4MSEC filing	+10.3%from $94.7M
Dec 31, 2024Reported Mar 24, 2025	-$0.14Reported	No estimate	$393.4M · FYSEC filing	No year-ago quarter

Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.

Open: $4.10
High: $4.24
Low: $3.67
Prev close: $4.20
52-wk high: $7.13
52-wk low: $2.32
Mkt cap: $428.4M
ROE: +0.0%
Beta: 0.41
P/S: 0.7x
P/B: 0.8x
Profit margin: -5.7%
Op margin: -3.4%

Fundamentals

Is the business strong?

This company is not yet profitable.

Net margin: -5.7%
Market cap: $428M

Valuation

P/S0.69
P/B0.76

Quality

Operating margin-3.4%
ROE0.0%
ROA-7.5%

Growth

Beta0.41

Technicals

Price structure

This stock is under pressure, and looks oversold after a sharp drop.

Trend

Under pressure

0 / 100

RSI 14

27oversold

20D volatility

235%annualized

52-week range

$3.75

$2.32$7.13

20D support

$3.35recent floor

20D resistance

$7.04recent ceiling

Returns

5D -44.0%20D -45.7%60D -43.7%

Price vs moving averages

SMA20 -36.9%SMA50 -40.2%SMA200 -21.5%

Volume pace

2.67xvs prior 20D

Quarter / reported

Earnings per share

Beat or miss

Revenue / income

Revenue vs last year

Sep 30, 2026Nov 5, 2026

-$0.13est. -$0.07

-$0.06

$169.8MSEC filing

+24.3%from $136.6M

Jun 30, 2026Aug 6, 2026

-$0.08est. -$0.07

-$0.01

$161.3MSEC filing

+34.6%from $119.8M

Mar 31, 2026May 8, 2026

-$0.02est. -$0.09

+$0.07

$147.4MSEC filing

+41.2%from $104.4M

Dec 31, 2025Mar 13, 2026

-$0.06est. -$0.09

+$0.03

$142.0MYahoo Finance

No year-ago quarter

Sep 30, 2025Nov 14, 2025

-$0.14est. -$0.11

-23.57%

$136.6MSEC filing

+36.7%from $99.9M

Jun 30, 2025Aug 14, 2025

-$0.15est. -$0.12

-25.00%

$119.8MSEC filing

+21.5%from $98.6M

Mar 31, 2025May 15, 2025

-$0.21Reported

No estimate

$104.4MSEC filing

+10.3%from $94.7M

Dec 31, 2024Mar 24, 2025

-$0.14Reported

No estimate

$393.4M · FYSEC filing

No year-ago quarter

Starling Oncology, Inc.

Smart money at a glance

What do analysts expect?

Questions about STLN filings

Smart money on STLN

Questions about STLN filings

What insiders are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in $0.06 a share below what analysts expected.

What the street expects next

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

Starling Oncology, Inc.

Smart money at a glance

What do analysts expect?

Questions about STLN filings

Smart money on STLN

Questions about STLN filings

What insiders are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in $0.06 a share below what analysts expected.

What the street expects next

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

Starling Oncology, Inc.

Overview

Questions about STLN filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.

Starling Oncology, Inc.

Overview

Questions about STLN filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.